WAVE LIFE SCIENCES LTD. Capital Expenditures Incurred but Not yet Paid
WAVE LIFE SCIENCES LTD. (WVE) reported Capital Expenditures Incurred but Not yet Paid of $1.85 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2018-11-09
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for the quarter ending 2018-09-30 was $1.30M.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for the quarter ending 2018-06-30 was $86.00K, a 681.82% increase year-over-year.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for the quarter ending 2018-03-31 was $469.00K, a 84.24% decline year-over-year.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for the quarter ending 2017-12-31 was -$1.08M, a 1962.07% decline year-over-year.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for fiscal 2017 was $339.00K, a 79.49% decline from fiscal 2016.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for fiscal 2016 was $1.65M, a 440.20% increase from fiscal 2015.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for fiscal 2015 was $306.00K, a 10100.00% increase from fiscal 2014.
- WAVE LIFE SCIENCES LTD. capital expenditures incurred but not yet paid for fiscal 2014 was $3.00K, a 94.00% decline from fiscal 2013.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2018-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.38M derived: sum of 2 quarters · filed 2018-11-09 | $1.85M 10-Q · filed 2018-11-09 | $773.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $555.00K 10-Q · filed 2018-08-09 | -$525.00K derived: sum of 3 quarters · filed 2018-08-09 | -$2.09M derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-03-31 | $469.00K 10-Q · filed 2018-05-09 | -$611.00K derived: sum of 2 quarters · filed 2018-05-09 | -$2.18M derived: sum of 3 quarters · filed 2018-11-09 | -$2.17M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$2.65M derived: sum of 2 quarters · filed 2018-11-09 | -$2.64M derived: sum of 3 quarters · filed 2018-11-09 | $339.00K 10-K · filed 2018-03-12 |
| 2017-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$1.56M derived: sum of 2 quarters · filed 2018-11-09 | $1.42M 10-Q · filed 2018-11-09 | $1.48M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.99M 10-Q · filed 2018-08-09 | $3.04M derived: sum of 3 quarters · filed 2018-08-09 | $3.60M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $2.98M 10-Q · filed 2018-05-09 | $3.03M derived: sum of 2 quarters · filed 2018-05-09 | $3.59M derived: sum of 3 quarters · filed 2018-05-09 | $4.44M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $614.00K derived: sum of 2 quarters · filed 2018-03-12 | $1.47M derived: sum of 3 quarters · filed 2018-03-12 | $1.65M 10-K · filed 2018-03-12 |
| 2016-09-30 | $556.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.41M derived: sum of 2 quarters · filed 2017-11-09 | $1.59M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $854.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.04M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $185.00K 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $306.00K 10-K · filed 2018-03-12 | |||
| 2015-06-30 | $114.00K 10-Q · filed 2016-08-15 | |||
| 2014-12-31 | $3.00K 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $50.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |